GLMD

Galmed Pharmaceu

• Benzinga·05/15 12:06

  12 Health Care Stocks Moving In Friday's Pre-Market Session

• TipRanks·05/14 12:19

  Galmed Reports Fivefold Bioavailability Boost with New Aramchol Meglumine Oral Formulation

• TipRanks·05/14 11:53

  Galmed reports results from first-in-man PK study of Aramchol Meglumine

• Benzinga·05/14 11:38

  Galmed Pharmaceuticals Announces Milestone Results From Phase 1 PK Study In Healthy Subjects; 400mg AM Increases Bioavailability By ~500% In Comparison To Aramchol Free Acid 300mg

• Reuters·05/14 11:30

  GALMED ANNOUNCES RESULTS FROM FIRST-IN-MAN PHARMACOKINETICS STUDY OF ORAL FORMULATION OF ARAMCHOL MEGLUMINE (AM); 400MG AM INCREASES BIOAVAILABILITY BY ~500% IN COMPARISON TO ARAMCHOL FREE ACID (AA) 300MG

• PR Newswire·05/14 11:30

  Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg

• TipRanks·05/07 07:22

  Galmed partnering with Tissue Dynamics to develop cardiac fibrosis platform

• TipRanks·05/06 12:19

  Galmed Pharmaceuticals Partners with Tissue Dynamics on Human Cardiac Fibrosis Platform

• Benzinga·05/06 11:37

  Tissue Dynamics, Galmed Pharmaceuticals Partner To Develop Novel Human Chronic Fibrosis Model

• Reuters·05/06 11:31

  TISSUE DYNAMICS AND GALMED PHARMACEUTICALS TO DEVELOP HUMAN-CENTERED CHRONIC CARDIAC FIBROSIS PLATFORM TO ADVANCE ARAMCHOL-BASED THERAPEUTICS

• PUBT·05/06 11:30

  Galmed partners Tissue Dynamics to develop chronic cardiac fibrosis organoid platform

• PR Newswire·05/06 11:30

  Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics

• Benzinga·04/28 21:05

  12 Health Care Stocks Moving In Tuesday's After-Market Session

• Benzinga·04/24 21:05

  12 Health Care Stocks Moving In Friday's After-Market Session

• TipRanks·04/15 15:00

  Analysts’ Opinions Are Mixed on These Healthcare Stocks: Galmed Pharmaceuticals (GLMD), Neurocrine (NBIX) and Mesoblast (MESO)